XML 28 R19.htm IDEA: XBRL DOCUMENT
v3.24.3

Company information - (Details) € / shares in Units, $ in Millions |  |  |  |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 16, 2024 item | Mar. 18, 2024 EUR (€) g | Feb. 01, 2024 item | Jan. 18, 2024 EUR (€) | Jan. 04, 2024 EUR (€) shares | Oct. 11, 2023 ¥ / shares | Oct. 11, 2023 € / shares | Jan. 31, 2023 item | Jun. 30, 2024 EUR (€) | Dec. 31, 2022 | Jan. 18, 2024 USD ($) | Oct. 18, 2023 EUR (€) | Oct. 18, 2023 USD ($) | Sep. 26, 2023 | May 16, 2022 EUR (€)
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan obtained |  |  |  |  |  |  |  |  | € 24,911,000 |  |  |  |  |  |
Total amount of loan | $ |  |  |  |  |  |  |  |  |  |  | $ 25 |  |  |  |
Finance contract with EIB |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan obtained |  |  |  | € 25,000,000 |  |  |  |  |  |  |  |  |  |  |
Total amount of loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 50,000,000
Finance contract with EIB, first tranche (Tranche A) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan obtained |  |  |  |  |  |  |  |  | € 25,000,000.0 |  |  |  |  |  |
Finance contract with EIB, second tranche (Tranche B) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan obtained |  |  |  |  | € 25,000,000.0 |  |  |  |  |  |  |  |  |  |
Number of shares underlying in EIB | shares |  |  |  |  | 3,144,654 |  |  |  |  |  |  |  |  |  |
Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum duration of Phase III trial |  |  |  |  |  |  |  | 7 years |  | 840 days |  |  |  |  |
Number of Biopsies Under the Phase III trial | item |  |  | 2 |  |  |  |  | 3 |  |  |  |  |  |  |
Number of weeks under the active treatment extension study |  |  |  |  |  |  |  | 336 days |  |  |  |  |  |  |
Licensing agreement with Hepalys |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment receivable |  |  |  |  |  |  |  |  |  |  |  | € 9,500,000 | $ 10 |  |
Maximum milestone payments receivable | $ |  |  |  |  |  |  |  |  |  |  |  |  | $ 231 |  |
Licensing agreement with Hepalys | Hepalys Pharma, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.00% |
Purchase of interests in investments accounted for using equity method, price per share | (per share) |  |  |  |  |  | ¥ 300 | € 1.90 |  |  |  |  |  |  |  |
Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy |  | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Daily dose of lanifibranor in trial | g |  | 0.800 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage reduction in results on treatments |  | 1.14% |  |  |  |  |  |  |  |  |  |  |  |  |
Reduction in hepatic steatosis (in percent) |  | (47.00%) |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of patients treated in trial |  | 83.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Significant relative reduction in VAT/SAT ratio (in percent) |  | (5.00%) |  |  |  |  |  |  |  |  |  |  |  |  |
Combination of lanifibranor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patients in main cohort |  | 63 |  |  |  |  |  |  |  |  |  |  |  |  |
Daily dose of lanifibranor in trial | g |  | 0.800 |  |  |  |  |  |  |  |  |  |  |  |  |
Daily dose of empagliflozin in trial | g |  | 0.010 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage reduction in results on treatments |  | 1.59% |  |  |  |  |  |  |  |  |  |  |  |  |
Reduction in hepatic steatosis (in percent) |  | (38.00%) |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of patients treated in trial |  | 67.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Significant relative reduction in VAT/SAT ratio (in percent) |  | (17.00%) |  |  |  |  |  |  |  |  |  |  |  |  |
Treatment period under study |  | 168 days |  |  |  |  |  |  |  |  |  |  |  |  |
Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of increase observed in the placebo arm |  | 0.26% |  |  |  |  |  |  |  |  |  |  |  |  |
Reduction in hepatic steatosis (in percent) |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Significant relative reduction in VAT/SAT ratio (in percent) |  | 11.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patients randomized | item | 900 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patients to be treated for 48 weeks | item | 360 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patients to be treated for 72 weeks | item | 80 |  |  |  |  |  |  |  |  |  |  |  |  |  |
NATiV3 Phase III clinical trial | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Treatment period under study | 504 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
NATiV3 Phase III clinical trial | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Treatment period under study | 336 days |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The nominal or face amount of a financial instrument, used to calculate payments made on that instrument. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_NotionalAmount
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from borrowings obtained. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2023-01-01 -Paragraph 17 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of daily dosage of empagliflozin in the trial. + References No definition available. + Details
Name: | iva_DailyDoseOfEmpagliflozinInTrial
Namespace Prefix: | iva_
Data Type: | dtr-types:massItemType
Balance Type: | na
Period Type: | duration

X
- Definition Daily dose of lanifibranor in trial + References No definition available. + Details
Name: | iva_DailyDoseOfLanifibranorInTrial
Namespace Prefix: | iva_
Data Type: | dtr-types:massItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of increase of Hemoglobin in patients with MASH and T2D. + References No definition available. + Details
Name: | iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of reduction in Hemoglobin among patients with MASH and T2D. + References No definition available. + Details
Name: | iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy + References No definition available. + Details
Name: | iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of reduction in Hepatic Steatosis measured by MRI-PDFF. + References No definition available. + Details
Name: | iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of significant relative reduction in VAT / SAT ratio in patients. + References No definition available. + Details
Name: | iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References No definition available. + Details
Name: | iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References No definition available. + Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems
Namespace Prefix: | iva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements. + References No definition available. + Details
Name: | iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements. + References No definition available. + Details
Name: | iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum duration of the clinical trial of the entity. + References No definition available. + Details
Name: | iva_MaximumDurationOfClinicalTrial
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the number of clinical trial. + References No definition available. + Details
Name: | iva_NumberOfBiopsiesUnderClinicalTrials
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of subjects randomized for main cohort. + References No definition available. + Details
Name: | iva_NumberOfPatientsRandomizedClinicalTrialMainCohort
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of patients randomized for treatment. + References No definition available. + Details
Name: | iva_NumberOfPatientsRandomizedForTreatment
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of patients to be treated for 48 weeks. + References No definition available. + Details
Name: | iva_NumberOfPatientsToBeTreatedForFortyEightWeeks
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of patients to be treated for 72 weeks. + References No definition available. + Details
Name: | iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of weeks under the active treatment extension study of the entity. + References No definition available. + Details
Name: | iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option to acquire shares in company, percentage + References No definition available. + Details
Name: | iva_OptionToAcquireSharesInCompanyPercentage
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of patients treated in this trial. + References No definition available. + Details
Name: | iva_PercentageOfPatientsTreatedInTrial
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchase of interests in investments accounted for using equity method, price per share + References No definition available. + Details
Name: | iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare
Namespace Prefix: | iva_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Treatment period under study + References No definition available. + Details
Name: | iva_TreatmentPeriodUnderStudy
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_LicensingAgreementWithHepalysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=iva_HepalysPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |